SCHEMBL7023116

SCHEMBL7023116

CCC(=O)NCCCN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15187041 0.93 MEN1 (0.77)
SCHEMBL22171101 0.92 MEN1 (0.61)
SCHEMBL22171099 0.92 MEN1 (0.61)
SCHEMBL25887714 0.91 MEN1 (0.74)
SCHEMBL15856109 0.91 MEN1 (0.74)
SCHEMBL14608401 0.91 MEN1 (0.74)
SCHEMBL25885490 0.91 MEN1 (0.74)
SCHEMBL7478566 0.91 MEN1 (0.74)
SCHEMBL22203854 0.90 MEN1 (0.65)
Ammonia Solution, Strong SCHEMBL9256322 0.89 MEN1 (0.71)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110845415-A Environment-friendly synthesis method of 2-ethyl-4-methylimidazole 广州市固研电子材料有限公司 2020-02-28 CN claimed
EP-1064253-B1 ANTI-TUMOUR AGENTS ASTRAZENECA AB (SE) 2003-01-29 EP claimed
US-6346633-B1 TERT-AMINOPHENYLESTER OF ACID ASTRAZENECA AB (SE) 2002-02-12 US claimed
EP-1064253-A1 ANTI-TUMOUR AGENTS AstraZeneca AB (SE) 2001-01-03 EP claimed
WO-1999048857-A1 ANTI-TUMOUR AGENTS ASTRAZENECA AB (SE) 1999-09-30 WO claimed
US-4775755-A DIAMINOPROPANE OR TETRAHYDROPYRIMIDINE REACTED WITH FORMAMIDE STAMICARBON B. V. (NL) 1988-10-04 US claimed
US-20250188110-A1 SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) 2025-06-12 US disclosed
WO-2024094645-A1 NONSTICK POLYMER COATINGS FOR SHORT-TERM IMPLANTS Universität Siegen (DE) 2024-05-10 WO disclosed
US-11779560-B2 Methods of using nitric oxide donor compounds for treatment of COVID-19 and other infectious diseases COEURATIVE, INC. (US) 2023-10-10 US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 US disclosed
WO-2023017152-A1 SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) 2023-02-16 WO disclosed
CN-110845415-B Environment-friendly synthesis method of 2-ethyl-4-methylimidazole 广东固研电子材料有限公司 2022-12-16 CN disclosed
CN-110845415-B Environment-friendly synthesis method of 2-ethyl-4-methylimidazole 广东固研电子材料有限公司 2022-12-16 CN disclosed
EP-2253611-A1 Low molecular weight quaternary ammonium salt dispersants Xerox Corporation (US) 2010-11-24 EP disclosed
US-7417164-B2 Fluorescent dyes for use in glucose sensing GLUMETRICS INC. (US) 2008-08-26 US disclosed
US-20080027245-A1 FLUORESCENT DYES FOR USE IN GLUCOSE SENSING GLUMETRICS INC. (US) 2008-01-31 US disclosed
EP-1064253-B1 ANTI-TUMOUR AGENTS ASTRAZENECA AB (SE) 2003-01-29 EP disclosed
US-6346633-B1 TERT-AMINOPHENYLESTER OF ACID ASTRAZENECA AB (SE) 2002-02-12 US disclosed
EP-1064253-A1 ANTI-TUMOUR AGENTS AstraZeneca AB (SE) 2001-01-03 EP disclosed
WO-1999048857-A1 ANTI-TUMOUR AGENTS ASTRAZENECA AB (SE) 1999-09-30 WO disclosed